Join the Chronic Lymphocytic Leukemia (CLL) group to help and get support from people like you.
Chronic Lymphocytic Leukemia (CLL) News
Related terms: Cancer, Chronic Lymphocytic Leukemia, Leukemia, Chronic Lymphocytic, CLL
Statin Use Improves Outcomes in Chronic, Small Lymphocytic Leukemia
WEDNESDAY, April 30, 2025 – For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless of treatment...
Disparities Identified in Leukemia Incidence, Mortality in Florida
TUESDAY, March 25, 2025 – There are racial and geographic disparities in the incidence of and mortality from adult leukemia in Florida, where the incidence of leukemia is the highest in the United...
Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia
FRIDAY, Feb. 21, 2025 – For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax with or without obinutuzumab significantly prolongs...
American Society of Hematology, Dec. 7 to 10
The annual meeting of the American Society of Hematology was held from Dec. 7 to 10 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical ...
Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
THURSDAY, June 27, 2024 – Immunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among...
Improved Outcomes Seen With Ibrutinib in Chronic Lymphocytic Leukemia
FRIDAY, June 21, 2024 – First-line ibrutinib is associated with better outcomes than chemoimmunotherapy among patients with chronic lymphocytic leukemia (CLL), according to a study published online...
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
PRINCETON, N.J.--(BUSINESS WIRE) Mar 14, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi ® ...
Johnson & Johnson Announces Expansion of Imbruvica (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications
HORSHAM, PA. February 26, 2024 – Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced today that the U.S. Food and Drug Administration (FDA) h...
FDA Approves Label Update for Brukinsa (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of Brukinsa versus Imbruvica® (ibrutinib) in Relapsed or Refractory CLL ALPINE is the ...
Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have...
Brukinsa (zanubrutinib) Approved in the U.S. for Chronic Lymphocytic Leukemia
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. – January 19, 2023 --(BUSINESS WIRE)-- BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S....
Calquence Tablet Formulation Approved in the US Across Current indications
New formulation can be co-administered with gastric acid-reducing agents Tablet offers equivalent efficacy, safety and consistent dosing compared to current capsule 5 August 2022 – AstraZeneca’s n...
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to...
FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
21 November 2019 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or s...
FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan
July 23, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab),1 for the treatment...